1.2 List of Figures
Figure 1: Cancer Immunotherapies Drugs Market, Global, Frequency of Molecular Aberrations in Non-Small Cell Lung Cancer (%), 2018 34
Figure 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Breast Cancer, 2016-2023 38
Figure 3: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Leukemia, 2016-2023 39
Figure 4: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Lymphoma, 2016-2023 40
Figure 5: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Cutaneous Melanoma, 2016-2023 41
Figure 6: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for NSCLC, 2016-2023 42
Figure 7: Cancer Immunotherapies Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 50
Figure 8: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Revlimid ($bn), 2006-2024 52
Figure 9: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Opdivo ($bn), 2014-2024 55
Figure 10: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Keytruda ($bn), 2014-2024 57
Figure 11: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Tecentriq ($bn), 2016-2024 59
Figure 12: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Darzalex ($bn), 2015-2024 60
Figure 13: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Imfinzi ($bn), 2017-2024 62
Figure 14: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2006-2024 64
Figure 15: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2024 66
Figure 16: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yescarta ($bn), 2018-2024 68
Figure 17: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gazyva ($bn), 2013-2024 69
Figure 18: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yervoy ($bn), 2011-2024 71
Figure 19: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024 73
Figure 20: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Kymriah ($bn), 2017-2024 75
Figure 21: Cancer Immunotherapies Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 76
Figure 22: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Stage of Development, Molecule Type and Program Type, 2018 77
Figure 23: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 78
Figure 24: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018 79
Figure 25: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Molecular Target, 2018 81
Figure 26: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018 82
Figure 27: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018 83
Figure 28: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2018 84
Figure 29: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2018 85
Figure 30: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2018 86
Figure 31: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 87
Figure 32: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018 88
Figure 33: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018 89
Figure 34: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2018 90
Figure 35: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 91
Figure 36: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2018 92
Figure 37: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2018 93
Figure 38: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2018 94
Figure 39: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 95
Figure 40: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2018 96
Figure 41: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2018 97
Figure 42: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2018 98
Figure 43: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Lisocabtagene maraleucel ($m), 2018-2024 100
Figure 44: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Durvalumab plus Tremelimumab ($m), 2018-2024 101
Figure 45: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tremelimumab ($m), 2018-2024 103
Figure 46: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cemiplimab ($m), 2019-2024 104
Figure 47: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Epacadostat ($bn), 2020-2024 105
Figure 48: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Axalimogene filolisbac ($m), 2020-2024 107
Figure 49: Cancer Immunotherapies Drugs Market, Global, Market Size ($bn), 2017-2024 108
Figure 50: Cancer Immunotherapies Drugs Market, Global, Key Products Market Share, 2017-2024 112
Figure 51: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024 113
Figure 52: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune Checkpoint Proteins ($bn), 2017-2024 114
Figure 53: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2017-2024 116
Figure 54: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cytokine Signaling ($bn), 2017-2024 117
Figure 55: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for HPV Vaccines ($bn), 2017-2024 118